Whalesbook
📉 The Financial Deep Dive
Gujarat Fluorochemicals Limited (GFCL) presented a bifurcated financial picture for the quarter and nine months ended December 31, 2025. On a standalone basis, the company registered a revenue of ₹1,026 Cr, marking an 8.7% decrease year-on-year (YoY). Profit After Tax (PAT) followed suit, declining by 15.5% YoY to ₹172 Cr. Despite this, standalone EBITDA showed resilience, inching up by 7.3% YoY to ₹307 Cr, though Earnings Per Share (EPS) contracted to ₹11.56 from ₹13.93 YoY.
The consolidated performance mirrored the standalone trend for the quarter, with revenue down 1.0% YoY to ₹1,136 Cr and PAT seeing a steeper fall of 19.0% YoY to ₹102 Cr. Consolidated EBITDA also decreased by 6.5% YoY to ₹275 Cr, and consolidated EPS stood at ₹9.29, down from ₹11.47 YoY.
However, the nine-month period paints a more optimistic, albeit selective, scenario. Standalone revenue for the nine months ended December 31, 2025, was ₹3,331 Cr (YoY -2.2%), and PAT stood at ₹682 Cr (YoY -7.8%). In contrast, consolidated revenue grew by 3.3% YoY to ₹3,627 Cr, and consolidated PAT demonstrated significant momentum with a 31.0% YoY increase to ₹465 Cr.
🔍 The Quality & Context
The results incorporated an exceptional item of ₹17 Cr in consolidated statements, attributed to the impact of New Labour Codes on employee benefits. Financial health indicators suggest manageable debt, with a consolidated Debt/Equity ratio of 0.26. However, a key concern is the contraction in operating margins. The consolidated operating margin for Q3 FY26 was 15.23%, a notable drop from 18.06% in the prior year's quarter, indicating increased cost pressures or reduced pricing power.
GFCL also made strategic investments during the quarter, injecting ₹92.47 Cr into GFCL EV Products Limited and ₹3.75 Cr into Flurry Wind Energy Private Limited. A composite scheme of arrangement involving ILFL, IHIL, and GFCL is awaiting regulatory approvals, which could shape future corporate structure.
🚩 Risks & Outlook
The primary risks for investors revolve around the sustained pressure on operating margins and the lack of specific forward-looking guidance from the management. While the nine-month consolidated PAT growth is a positive sign, the sequential decline in Q3 performance warrants close monitoring. The pending regulatory approvals for the scheme of arrangement add another layer of uncertainty. Investors will be keenly watching for recovery in standalone performance and margin improvement in the upcoming quarters.